Keywords: priority, review, s-p, temodar, snda, drug, major

Priority review for S-P's Temodar sNDA

Article | 08 November 2004

Print This

US drug major Schering-Plough says that the US Food and Drug Administration has granted six-month priority review status to its ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in